A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
A Phase III Randomised, Double-Blind, Factorial Design Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on Low-Density Lipoprotein Cholesterol in Lipid-Lowering Treatment-Naïve Patients
AstraZeneca
600 participants
Aug 12, 2026
INTERVENTIONAL
Conditions
Summary
This is a study to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients. Laroprovstat is a small molecule that reduces the amount of LDL-C in the blood. Laroprovstat and FDC laroprovstat/rosuvastatin are being developed for the treatment of hypercholesterolaemia.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
daily oral dose of the Laroprovstat
daily oral dose of the Rosuvastatin 1
daily oral dose of the Rosuvastatin 2
daily oral dose of the Laroprovstat/Rosuvastatin 1
daily oral dose of the Placebo to match Rosuvastatin
daily oral dose of the Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1
daily oral dose of the Laroprovstat/Rosuvastatin 2
daily oral dose of the Placebo to match Laroprovstat/Rosuvastatin 2
Locations(152)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07619131